ADVERTISEMENT

Ratnamani Metals Shares Hit Record High After Q4 Profit Jumps 73%

The company's net profit surged 73% year-on-year to Rs 192.58 crore in the quarter ended March.

<div class="paragraphs"><p>Pipe coating solutions by Ratnamani Metals and Tubes Ltd. (Source: Company website)</p></div>
Pipe coating solutions by Ratnamani Metals and Tubes Ltd. (Source: Company website)
Show Quick Read
Summary is AI Generated. Newsroom Reviewed

Shares of Ratnamani Metals & Tubes Ltd. surged to a record high on Thursday after its net profit jumped 73% in the fourth quarter.

The company's net profit rose 73% year-on-year to Rs 192.58 crore in the quarter ended March, according to its exchange filing. The company's March quarter revenue was up 54% to Rs 1,499 crore.

The board also recommended raising Rs 500 crore in one or more tranches in the form of non-convertible debentures by way of private placement.

Opinion
Stock Market Today: Sensex, Nifty End Volatile Session Lower Ahead Of MSCI Rejig

Ratnamani Metals & Tubes Q4 (Consolidated, YoY)

  • Revenue is up 54% at Rs 1,499 crore.

  • Ebitda up 4.02% at Rs 300.56 crore.

  • Ebitda margin at 20.1% vs. 17.3%.

  • Net profit is up 73% at Rs 192.58 crore.

  • The board recommended a dividend of Rs 12 per equity share for FY23.

Opinion
Dr. Reddy's Q4 Results Review: Shares Fall On Profit Miss, Analyst Downgrades

Shares of Ratnamani Metals rose 8.23% to Rs 2,424 apiece, compared to a 0.07% advance in the benchmark NSE Nifty 50 as of 11:04 a.m.

The stock gained as much as 12.97% intraday, the most in over 10 months since June 30, 2022. The stock hit an all-time high of Rs 2,582 apiece, intraday. Total traded volume stood at 56.3 times its 30-day average. The relative strength index was at 79, implying that the stock may be overbought.

Out of the six analysts tracking the company, five maintain a 'buy' rating and one recommends a 'hold' on the stock, according to Bloomberg data.

The average 12-month consensus price target implies a potential downside of 1.9%.

Opinion
Diagnostics May Have A Different Growth Trajectory, Says InCred's Aditya Khemka
OUR NEWSLETTERS
By signing up you agree to the Terms & Conditions of NDTV Profit